MENU
+Compare
NPCE
Stock ticker: NASDAQ
AS OF
May 13 closing price
Price
$12.95
Change
-$0.42 (-3.14%)
Capitalization
385.2M

NPCE Neuropace Forecast, Technical & Fundamental Analysis

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures... Show more

NPCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NPCE with price predictions
May 12, 2025

NPCE's Stochastic Oscillator stays in overbought zone for 2 days

Expect a price pull-back in the near future.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

NPCE broke above its upper Bollinger Band on May 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 25, 2025. You may want to consider a long position or call options on NPCE as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NPCE just turned positive on April 25, 2025. Looking at past instances where NPCE's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

NPCE moved above its 50-day moving average on May 06, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NPCE crossed bullishly above the 50-day moving average on May 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NPCE advanced for three days, in of 217 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 150 cases where NPCE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NPCE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.657) is normal, around the industry mean (24.179). P/E Ratio (0.000) is within average values for comparable stocks, (79.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (42.574).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NPCE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

View a ticker or compare two or three
NPCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NPCE is expected to report earnings to rise 34.33% to -24 cents per share on May 13

Neuropace NPCE Stock Earnings Reports
Q1'25
Est.
$-0.24
Q4'24
Beat
by $0.07
Q3'24
Beat
by $0.08
Q2'24
Beat
by $0.04
Q1'24
Est.
$-0.32
The last earnings report on March 04 showed earnings per share of -18 cents, beating the estimate of -25 cents. With 212.00K shares outstanding, the current market capitalization sits at 385.20M.
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
455 N. Bernardo Avenue
Phone
+1 650 237-2700
Employees
167
Web
https://www.neuropace.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA334.0715.69
+4.93%
Tesla
BTC.X104169.8100001356.851600
+1.32%
Bitcoin cryptocurrency
GME28.390.34
+1.21%
GameStop Corp
AAPL212.932.14
+1.02%
Apple
SPY586.843.85
+0.66%
SPDR® S&P 500® ETF

NPCE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NPCE has been loosely correlated with FNA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NPCE jumps, then FNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPCE
1D Price
Change %
NPCE100%
+3.72%
FNA - NPCE
43%
Loosely correlated
N/A
STVN - NPCE
37%
Loosely correlated
-1.42%
SMTI - NPCE
32%
Poorly correlated
+6.24%
NTRA - NPCE
32%
Poorly correlated
+3.51%
HBIO - NPCE
32%
Poorly correlated
+11.78%
More